BR0112460A - Método para tratamento de sépsis - Google Patents

Método para tratamento de sépsis

Info

Publication number
BR0112460A
BR0112460A BR0112460-9A BR0112460A BR0112460A BR 0112460 A BR0112460 A BR 0112460A BR 0112460 A BR0112460 A BR 0112460A BR 0112460 A BR0112460 A BR 0112460A
Authority
BR
Brazil
Prior art keywords
sepsis treatment
treatment
sepsis
sepis
prevention
Prior art date
Application number
BR0112460-9A
Other languages
English (en)
Inventor
Andrew Loh
William Louis Macias
Simona Skerjanec
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR0112460A publication Critical patent/BR0112460A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Apparatuses For Bulk Treatment Of Fruits And Vegetables And Apparatuses For Preparing Feeds (AREA)

Abstract

"MéTODO PARA TRATAMENTO DE SéPSIS". Um novo método de tratamento e/ou prevenção de sépsis.
BR0112460-9A 2000-07-14 2001-06-29 Método para tratamento de sépsis BR0112460A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21892800P 2000-07-14 2000-07-14
US25639800P 2000-12-18 2000-12-18
PCT/US2001/016509 WO2002005796A2 (en) 2000-07-14 2001-06-29 Use of a spla2 inhibitor for the treatment of sepsis

Publications (1)

Publication Number Publication Date
BR0112460A true BR0112460A (pt) 2003-07-22

Family

ID=26913393

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0112460-9A BR0112460A (pt) 2000-07-14 2001-06-29 Método para tratamento de sépsis

Country Status (7)

Country Link
EP (1) EP1303262A2 (pt)
JP (1) JP2004503586A (pt)
CN (1) CN1450893A (pt)
AU (1) AU2001272915A1 (pt)
BR (1) BR0112460A (pt)
CA (1) CA2413582A1 (pt)
WO (1) WO2002005796A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5584518B2 (ja) * 2009-05-28 2014-09-03 石原産業株式会社 ジアミノトリフルオロメチルピリジン誘導体を含有する抗ショック剤
EP3693063A1 (en) * 2019-02-06 2020-08-12 Diaccurate Methods and compositions for treating cancer
CN112022846B (zh) * 2020-09-23 2021-10-08 吕奔 一种吲哚啉衍生物在制备治疗脓毒症药物中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
TW383302B (en) * 1994-04-01 2000-03-01 Lilly Co Eli 1H-indole-3-glyoxylamide sPLA2 inhibitors
US5641800A (en) * 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
CA2264020A1 (en) * 1996-08-26 1998-03-05 Jean Bemis Inhibitors of phospholipase enzymes
AU6229298A (en) * 1997-02-20 1998-09-09 Shionogi & Co., Ltd. Indole dicarboxylic acid derivatives
CA2309135A1 (en) * 1997-10-27 1999-05-06 Michael Lyle Denney N,n-diethylglycolamido ester prodrugs of indole spla2 inhibitors
DE69830335T2 (de) * 1997-10-27 2006-02-02 Eli Lilly And Co., Indianapolis MORPHOLINO-N-ETHYL ESTER PRODROGEN VON INDOL sPLA 2 HEMMER
AU1200799A (en) * 1997-10-27 1999-05-17 Eli Lilly And Company Isopropyl ester prodrugs of indole spla2 inhibitors
EE200000522A (et) * 1998-02-25 2002-02-15 Genetics Institute, Inc. Fosfolipaas A2 ensüümi inhibiitor, seda sisaldav farmatseutiline kompositsioon ning meetod fosfolipaasensüümi toime pärssimiseks
EP1058547B1 (en) * 1998-03-03 2005-11-23 Shionogi & Co., Ltd. Pharmaceutical compositions containing the phospholipase inhibitor sodium 3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1h-indol-4-yl]oxy]acetate
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.
ID23219A (id) * 1998-04-17 2000-03-30 Lilly Co Eli Trisiklik tersubstitusi
PL344571A1 (en) * 1998-05-01 2001-11-05 Lilly Co Eli Spla2
DE69931496T2 (de) * 1998-08-03 2006-11-23 Eli Lilly And Co., Indianapolis INDOLVERBINDUNGEN ALS sPLA2 INHIBITOREN
EP1100493A4 (en) * 1998-08-03 2001-10-24 Lilly Co Eli SPLA 2 INHIBITORS? OF THE INDOLTYPS
CA2358492A1 (en) * 1998-12-21 2000-06-29 Eli Lilly And Company Combination therapy for the treatment of sepsis
WO2000037358A1 (en) * 1998-12-22 2000-06-29 Eli Lilly And Company NOVEL sPLA2 INHIBITORS

Also Published As

Publication number Publication date
CA2413582A1 (en) 2002-01-24
WO2002005796A2 (en) 2002-01-24
CN1450893A (zh) 2003-10-22
AU2001272915A1 (en) 2002-01-30
WO2002005796A3 (en) 2002-09-06
JP2004503586A (ja) 2004-02-05
EP1303262A2 (en) 2003-04-23

Similar Documents

Publication Publication Date Title
BR9908280A (pt) Inibidores de enzimas de fosfolipase
BR9909242A (pt) Inibidores de fosfolipase a2
MY129409A (en) Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp)
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
BR9703302A (pt) Aparelho e método para a geração e uso de ìons férricos
BR0317715A (pt) Composições e processos de uso de collajolie
ATE225351T1 (de) Thienopyridin und thienopyrimidinderivate und ihre verwendung als entzündungshemmende mittel
DE60124684D1 (de) Sulfonamido-substituierte verbrückte bicycloalkylderivative
EE200100155A (et) Ateroskleroosi ravimeetod, kasutades aP2 inhibiitorit ja selle kombinatsiooni
PL367065A1 (en) Use of osteopontin for the treatment and/or prevention of neurologic diseases
BRPI0110506B8 (pt) uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose
BR9909819A (pt) Amida, uso de amidas, e, preparação farmacêutica para uso oral, parenteral ou intraperitoneal
DE60001735D1 (de) 1-aminotriazolo 4,3-a chinazolin-5-one und/oder -thione inhibitoren von phosphodiesterasen iv
AU2001262401A1 (en) Use of ellagic acid as anti-pollution cosmetic agent
MA26486A1 (fr) Aryl- et heteroaryl-thiazolocetohydrazides inhibiteurs de proteases, et compositions pharmaceutiques les contenant .
BR9901058A (pt) N-cail e n-aroil aralquil amidas.
BR0108980A (pt) Aplicação e formulação farmacêuticas compreendendo inibidor de reabsorção de norepinefrina
BR0112460A (pt) Método para tratamento de sépsis
MXPA02011558A (es) Inhibidores de mmp-2/mp-9 novedosos.
ATE299703T1 (de) Mmp-hemmer bei bindegewebserweichung
PT929299E (pt) 1,2,3,4-tetra-hidro-2-dibenzofuranaminas e 2-aminociclo-hepta ¬b| benzofuranos substituidos
ITMC20020011A1 (it) Metodo e relativo impianto per l'incisione laser di lastre o cilindricalcografici.
DE69930844D1 (de) Inhibitoren von mycobakterien
DE69838686D1 (de) Tripeptidylpeptidaseinhibitoren
TR200003084T2 (tr) Paroxetine askorbat

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired